The Discovery Oncology department is seeking an exceptional, highly motivated and creative scientist to independently propose and lead innovative research efforts focused on using chemical biology and/or functional genomics approaches to discover and validate novel synthetic lethal interactions in the context of cancer biology. The ideal candidate will have significant experience in cancer biology and cancer signaling pathways. A solid track record of publications (as corresponding senior author) in top tier journals is required with specific publications relating to the discovery of novel synthetic lethal vulnerabilities in cancer. The position will involve close collaboration with other research labs in Discovery Oncology as well as with other departments including Functional Genomics, Computational Biology, Translational Oncology, Cancer Immunotherapy and our core drug discovery groups.
The mission of Genentech’s Discovery Oncology department is to discover the next generation of oncology targets and therapeutics through in-depth interrogation of biological systems that will inform on tumor development, growth and signaling processes. We value scientists that take innovative approaches and delve deep into understanding the underlying mechanisms of cancer biology and therapeutic response, as it is essential to guide the optimal development of our therapies in the clinic. Our scientists are passionate about conducting groundbreaking science that can make a direct impact on patient’s lives. Examples of recent departmental publications include:
Reproducible pharmacogenomics profiling of cancer cell line panels
Haverty, P.M., Lin, E., Tan, J., Yu, Y., Lam, B., Lianoglou, S., Neve, R.M., Martin, S., Settleman, J., Yauch, R.L., and Bourgon, R.
Nature 2016 May 19;533(7603):333-7. doi: 10.1038/nature17987.
Metabolic plasticity underpins innate and acquired resistance to LDHA inhibition
Boudreau A, Purkey HE, Hitz A, Robarge K, Peterson D, Labadie S, Kwong M, Hong R, Gao M, Del Nagro C, Pusapati R, Ma S, Salphati L, Pang J, Zhou A, Lai T, Li Y, Chen Z, Wei B, Yen I, Sideris S, McCleland M, Firestein R, Corson L, Vanderbilt A, Williams S, Daemen A, Belvin M, Eigenbrot C, Jackson PK, Malek S, Hatzivassiliou G, Sampath D, Evangelista M, O'Brien T.
Nat Chem Biol. 2016 Oct;12(10):779-86. doi: 10.1038/nchembio.2143. Cover
Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.
Goldstein LD, Lee J, Gnad F, Klijn C, Schaub A, Reeder J, Daemen A, Bakalarski CE, Holcomb T, Shames DS, Hartmaier RJ, Chmielecki J, Seshagiri S, Gentleman R, Stokoe D.
Cell Reports 2016 Sep 6;16(10):2605-17. doi: 10.1016/j.celrep.2016.08.010.
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2.
Foster SA, Whalen DM, Özen A, Wongchenko MJ, Yin J, Yen I, Schaefer G, Mayfield JD, Chmielecki J, Stephens PJ, Albacker LA, Yan Y, Song K, Hatzivassiliou G, Eigenbrot C, Yu C, Shaw AS, Manning G, Skelton NJ, Hymowitz SG, Malek S.
Cancer Cell. 2016 Apr 11;29(4):477-93. doi: 10.1016/j.ccell.2016.02.010.
Therapeutic antibodies reveal Notch control of transdifferentiation in the adult lung.
Lafkas D, Shelton A, Chiu C, de Leon Boenig G, Chen Y, Stawicki SS, Siltanen C, Reichelt M, Zhou M, Wu X, Eastham-Anderson J, Moore H, Roose-Girma M, Chinn Y, Hang JQ, Warming S, Egen J, Lee WP, Austin C, Wu Y, Payandeh J, Lowe JB, Siebel CW.
Nature. 2015 Dec 3;528(7580):127-31. doi: 10.1038/nature15715. Epub 2015 Nov 18.
A Ph.D. in Biochemistry, Cell Biology or a related field is required with 3-6 years of relevant post-doctoral research experience and 8-10 years of academic experience as assistant/associate professor or industry experience at the group leader level. Competitive candidates are expected to be at a level commensurate with associate or full professor faculty positions at top ranked academic institutions. A strong track record of cutting edge research as evidenced by recent senior corresponding authored publications in top tier journals is required. Outstanding written and oral communication skills are essential as is the ability to lead a laboratory group and oversee research programs across cross-functional research teams.
A member of the Roche Group, Genentech has been at the forefront of the biotechnology industry for more than 40 years, using human genetic information to develop novel medicines for serious and life-threatening diseases. Genentech has multiple therapies on the market for cancer & other serious illnesses. Please take this opportunity to learn about Genentech where we believe that our employees are our most important asset & are dedicated to remaining a great place to work.
The next step is yours. To apply today, click on the "Apply online" button.
Genentech is an equal opportunity employer & prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital & veteran status. For more information about equal employment opportunity, visit our Genentech Careers page.
Genentech makes life-saving medicine. People make Genentech what it is. This video offers insights into who these people are and what it means to them to be working at Genentech.